{
    "nctId": "NCT05833919",
    "briefTitle": "Second Line ERIbulin Followed by CApecitabine or the Reverse Sequence in HER2-negative Metastatic Breast Cancer Patients",
    "officialTitle": "Second Line ERIbulin Followed by CApecitabine or the Reverse Sequence in HER2-negative Metastatic Breast Cancer (MBC) Patients: a Randomized Phase II Study - ERICA Trial",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 122,
    "primaryOutcomeMeasure": "Total Progression Free Survival (PFS-T)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Written informed consent (both for clinical and blood biomarker study)\n* Histological diagnosis of HER2 negative MBC\n* Females \u2265 18 years\n* Measurable disease (according RECIST criteria version 1.1)\n* Prior Anthracyclines and Taxanes in either (neo-) adjuvant or metastatic setting, unless the patient was not suitable for one of these treatments\n* 1 prior cytotoxic regimen for advanced or MBC (not including adjuvant or neo-adjuvant therapy). Patients with no prior cytotoxic regimens for advanced or metastatic disease will only be allowed if they relapsed during or within 6 months of (neo-) adjuvant cytotoxic therapy that included anathracyclines and/or taxanes (see prior criteria);\n* Prior hormonotherapy and Cyclines inhibitors are allowed, so as indicated in the international guidelines for the management of hormone positive breast cancer (ER and/or PR positive);\n* ECOG Performance Status \u2264 2\n* Absence of angina or heart failure or infarction within 12 months from inclusion\n* Adequate bone marrow and organ function as follows (haemoglobin \u22659.0 g/dl; absolute neutrophil count \u2265 1.5x103/mm3; plateled count \u2265 100x103/mm3; bilirubin levels \u2264 1.5 times Upper Limits of Normal\n* biliary stenting is allowed to resolve obstruction - Serum Transaminase level \u2264 2.5 times ULN; serum creatinine \u2264 1.5 times ULN;\n* Life expectancy of at least 12 weeks;\n* If women of childbearing potential (WOCBP) age: effective contraceptive measures must be used during the study treatment period and up to 3 months after the last dose of study drug.\n\nExclusion Criteria:\n\n* Unability to give informed consent\n* Absence of measurable disease\n* Concurrent active malignancies (except of in situ carcinoma of the cervix and inactive non-melanoma skin cancer)\n* Current active infection;\n* Serious pre-existing medical conditions or serious concomitant diseases;\n* systemic disorders that would compromise the safety of the patient or her ability to complete the study, at the discretion of the investigator (for example, unstable angina pectoris, or a clinically significant history of cardiac disease or uncontrolled diabetes mellitus);\n* Known immunodeficiency virus infection;\n* Pregnant or breastfeeding women\n* Unable to undergo medical test for geographical, social or psychological reason;\n* Active or symptomatic brain metastases;\n* Known complete Dihydropyrimidine dehydrogenase (DPD) deficiency (phenotype and/or genotype testing, according to applicable national guidelines, prior to the initiation of treatment with Capecitabine is recommended)\n* Recent or concomitant treatment with brivudine (there must be at least a 4-week waiting period between end of treatment with brivudine and start of capecitabine therapy).",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}